Physician profile
Robert Paul Olson
NPI 1245203058
$7,604.42
in general payments reported to CMS, 2019-2025
36 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $440 · 2021: $447 · 2022: $1,155 · 2023: $1,510 · 2024: $1,855 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,324.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,217.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,192.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $912.87 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $886.66 | 2020-2025 | |
| Pfizer INC. | $591.45 | 2022-2025 | |
| Exact Sciences Corporation | $469.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $396.99 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $253.11 | 2023-2025 | Spravato |
| Dynavax Technologies Corporation | $212.15 | 2022-2025 | Heplisav-B |
| Abbott Laboratories | $191.58 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $189.02 | 2019-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.59 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $134.10 | 2024-2025 | Voquezna |
| Axonics, INC. | $111.22 | 2023 | Axonics |
| Gilead Sciences, INC. | $98.22 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.